Endocannabinoids travel in tiny cell-derived particles during COVID-19 and increase with disease severity

What the researchers found

Except for anandamide, endocannabinoid concentrations (2-AG, SEA, PEA, OEA) were significantly higher in extracellular vesicles than in plasma, and these EV-endocannabinoid levels increased with COVID-19 severity. MicroRNA analysis revealed regulatory networks that appeared to fine-tune endocannabinoid signaling in immune cells.

Why it matters

This study suggests the body uses extracellular vesicles as a delivery system for endocannabinoids during infection, and that this system scales up during severe illness. Understanding this transport mechanism could inform future strategies for modulating inflammation.

The numbers in context

Five endocannabinoids measured: anandamide, 2-AG, SEA, PEA, and OEA. Four of five were significantly enriched in EVs versus plasma. Steroid hormones (cortisol, testosterone) showed no EV enrichment, suggesting specificity for lipophilic signaling molecules.

How the study worked

Researchers measured five endocannabinoids in both extracellular vesicles and plasma from COVID-19 patients of varying severity. RNA sequencing of EV-derived microRNAs and blood cell mRNA was used to construct signaling networks connecting endocannabinoid transport to immune cell regulation.

What this study cannot tell us

This is an observational study that cannot determine whether elevated EV-endocannabinoid levels are protective or harmful during COVID-19. Sample sizes were not specified in the abstract. The regulatory networks are inferred from correlation, not causation.

How to read the evidence

This is a preliminary observational study identifying a novel transport mechanism. While the finding is intriguing, the clinical significance remains unclear and the regulatory networks are correlational.

When this study was published

Published in 2024 using data from COVID-19 patients.

The bigger picture

The endocannabinoid system plays a role in immune regulation, but how these lipophilic molecules travel through the bloodstream has been unclear. This finding that EVs serve as transport vehicles opens new questions about how the body coordinates endocannabinoid-based immune responses.

Questions still open

• Are elevated EV-endocannabinoid levels a protective response or a marker of disease progression? Could therapeutic manipulation of this transport system modulate inflammation in severe infections? Do other inflammatory conditions show similar EV-endocannabinoid patterns?

Common questions

Read the original research

Extracellular Vesicles and Endocannabinoid Signaling in Patients with COVID-19.

Cannabis and cannabinoid research, 9(5), 1326-1338

Citation

Brandes, Florian; Keiler, Annekathrin M; Kirchner, Benedikt; Borrmann, Melanie; Billaud, Jean-Noël; Reithmair, Marlene; Klein, Matthias; Campolongo, Patrizia; Thieme, Detlef; Pfaffl, Michael W; Schelling, Gustav; Meidert, Agnes S. (2024). Extracellular Vesicles and Endocannabinoid Signaling in Patients with COVID-19.. Cannabis and cannabinoid research, 9(5), 1326-1338. https://doi.org/10.1089/can.2023.0040

Explore the wider topic

• CBD Oil Quality Guide: How to Avoid Snake Oil
• Anxiety After Quitting Weed: When to Consider Medication
• Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
• Cannabis for Chronic Pain: What the Research Actually Supports
• Cannabis and Epilepsy: The Epidiolex Story and What It Means
• Does CBD Actually Work for Anxiety? What the Evidence Shows
• Does CBD Help with Weed Withdrawal? What Studies Show
• CBD vs THC: The Differences That Actually Matter
• The Proven Medical Benefits of Cannabis: What Research Supports
• Quitting Weed Before Surgery
• Weed and Medications: What Changes When You Quit
• Quitting Weed During Pregnancy: What You Need to Know
• Quitting Weed While Pregnant: What You Need to Know
• Cannabis and Older Adults: Risks Seniors Should Know
• Cannabis and Breastfeeding: THC in Breast Milk